Gastroenterology
Volume 138, Issue 5 , Pages 1648-1652.e2 , May 2010

Colorectal Cancer Screening Guidelines: The Importance of Evidence and Transparency

  • James E. Allison

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: James E. Allison, MD, FACP, AGAF, Clinical Professor of Medicine Emeritus, University of California San Francisco UCSF Division of Gastroenterology San Francisco General Hospital Campus, 1001 Potrero Avenue, NH-3D, San Francisco, California 94110

References 

  1. Levin B, Lieberman DA, McFarland , et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–1595
  2. Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603–1607
  3. Allison JE, Tekawa IS, Ransom LJ, et al. A comparison of fecal occult blood tests for colorectal cancer screening. N Engl J Med. 1996;334:155–159
  4. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1–9
  5. Morikawa T, Kato J, Yamaji Y, et al. Comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology. 2005;129:422–428

 Conflicts of interest Dr. Allison has been an ad hoc consultant to Quidel Corporation, is a member of the Scientific Advisory Board for IntelligeneScan, and recently did a webinar on Screening for CRC for Beckman Coulter.

PII: S0016-5085(10)00335-5

doi: 10.1053/j.gastro.2010.03.001

Gastroenterology
Volume 138, Issue 5 , Pages 1648-1652.e2 , May 2010

Article Tools